D******9
发帖数: 2665 | 1 个人认为FDA会批准BYDUREON， 欧洲已经批准了， FDA要求的心率不齐的实验已经完成
， 没有问题。 唯一的问题是现在市场上已经有很多种治疗二型糖尿病的药， 不知道
能导致公司盈利。。。要是批准， 能50% UP, 要是有大药厂有兴趣买， 能DOUBLE | b**********k
发帖数: 1262 | 2 thanks for the info
do you have the link that europe approve it ? | y*****l
发帖数: 5997 | 3 Amylin is set for an FDA decision on its product candidate, Bydureon, on 01/
27/2012. Bydureon a glucagon-like peptide-1 receptor agonist, and would be
the first once-weekly treatment for type 2 diabetes in adults. It delivers
glycemic control in a single weekly dose. AMLN currently trades around $10.
50 with the highest sell-side analyst one year price target being $25. | D******9
发帖数: 2665 | 4 Bydureon Gains EU Approval
Print Share
By: Zacks Equity Research
June 22, 2011 |Comments: 0
Recommended this article (0)
LLY | ALKS | AMLN | NVO
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company
(LLY), and Alkermes, Inc. (ALKS), recently received a boost with the
European Commission granting marketing authorization to Bydureon (exenatide
once-weekly) for the treatment of type II diabetes.
Bydureon is the first once-weekly treatment to gain approval for type II
diabetes. Approval was granted for use in combination with metformin, a
sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or
metformin plus a thiazolidinedione.
EU Approval Was Expected
EU approval was expected as, earlier in April, Bydureon had received a
positive opinion from the European Medicines Agency’s (EMA) Committee for
Medicinal Products for Human Use (CHMP).
While anticipated, the final approval of Bydureon, nevertheless, comes as a
relief for Amylin which has recently been at the receiving end of a series
of disappointing pipeline-related news. In mid-March 2011, Amylin and its
partner Takeda Pharmaceutical Company Limited had announced the suspension
of clinical activities associated with a phase II study of their obesity
candidate.
Amylin and Takeda were studying the safety and efficacy of pramlintide/
metreleptin for the treatment of obesity. However, the companies decided to
voluntarily halt the trial in order to study a new antibody-related
laboratory finding associated with metreleptin in two patients. | D******9
发帖数: 2665 | | b**********k
发帖数: 1262 | | b****t
发帖数: 442 | | s**********9
发帖数: 846 | | s**********9
发帖数: 846 | 9 going up a little bit every day. | D******9
发帖数: 2665 | | b**********k
发帖数: 1262 | 11 嗯 连着3天十字星， intraday chart看着也像是很多大户在吸筹， 大阳棒比较多。
今天盘中也是好几个 10w 的大阳棒， 看来是开始发力了....
【在 D******9 的大作中提到】
: up 3% today, not bad
| s**********9
发帖数: 846 | | D******9
发帖数: 2665 | 13 up 3% again today. Let's see whether it will break through | b**********k
发帖数: 1262 | 14 大熊猫厉害， 我也是看到它贴了之后 才跟着进的，技术面的指标要有消息面的支撑才
行， 一个原因一个结果。
多谢大熊猫才是....
【在 s**********9 的大作中提到】
: 大熊猫和NJJ厉害!
|
|
